Search: onr:"swepub:oai:DiVA.org:umu-54130" >
A randomized, dose-...
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
-
- Nilsson, S. (author)
- Karolinska Institutet
-
- Strang, P. (author)
- Karolinska Institutet
-
Aksnes, A. K. (author)
-
show more...
-
- Franzen, Lars (author)
- Umeå universitet,Onkologi
-
Olivier, P. (author)
-
Pecking, A. (author)
-
Staffurth, J. (author)
-
Vasanthan, S. (author)
-
Andersson, C. (author)
-
Bruland, O. S. (author)
-
show less...
-
(creator_code:org_t)
- Oxford : Elsevier, 2012
- 2012
- English.
-
In: European Journal of Cancer. - Oxford : Elsevier. - 0959-8049 .- 1879-0852. ; 48:5, s. 678-686
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Purpose: To investigate the dose-response relationship and pain-relieving effect of radium-223, a highly bone-targeted alpha-pharmaceutical. Methods: One hundred patients with castration-resistant prostate cancer (CRPC) and painful bone metastases were randomized to a single intravenous dose of 5, 25, 50 or 100 kBq/kg radium-223. The primary end-point was pain index (visual analogue scale [VAS] and analgesic use), also used to classify patients as responders or non-responders. Results: A significant dose response for pain index was seen at week 2 (P = .035). At week 8 there were 40%, 63%, 56% and 71% pain responders (reduced pain and stable analgesic consumption) in the 5, 25, 50 and 100 kBq/kg groups, respectively. On the daily VAS, at week 8, pain decreased by a mean of -30, -31, -27 and -28 mm, respectively (P = .008, P = .0005, P = .002, and P < .0001) in these responders (post-hoc analysis). There was also a significant improvement in the brief pain inventory functional index for all dose-groups (P = .04, .01, .002 and .02, Wilcoxon signed rank test). Furthermore, a decrease in bone alkaline phosphatase in the highest dose-group was demonstrated (P = .0067). All doses were safe and well tolerated. Conclusion: Pain response was seen in up to 71% of the patients with a dose response observed 2 weeks after administration. The highly tolerable side-effect profile of radium-223 previously reported was confirmed. (C) 2012 Elsevier Ltd. All rights reserved.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Pain
- Bone metastases
- Prostate cancer
- Castration-resistant
- Alpha-pharmaceutical
- Radium
- Alpharadin
- BPI
- Functional index
Publication and Content Type
- ref (subject category)
- for (subject category)
Find in a library
To the university's database
- By the author/editor
-
Nilsson, S.
-
Strang, P.
-
Aksnes, A. K.
-
Franzen, Lars
-
Olivier, P.
-
Pecking, A.
-
show more...
-
Staffurth, J.
-
Vasanthan, S.
-
Andersson, C.
-
Bruland, O. S.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
European Journal ...
- By the university
-
Umeå University
-
Karolinska Institutet